Nomogram for Predicting Recurrence-Free Survival in Chinese Women with Endometrial Cancer after Initial Therapy: External Validation

Table 1

The clinicopathological characteristics of the training cohort.

Variables	Training cohort, n = 520
	(no. of patients) (%)
Age (years)
<60	339 (65.2)
≥60	181 (34.8)
Menopausal status
No	177 (34.0)
Yes	343 (66.0)
Depth of myometrial invasion
<50%	391 (75.2)
≥50%	129 (24.8)
Cervical stromal invasion
No	461 (88.7)
Yes	59 (11.3)
Adnexal involvement
No	492 (94.6)
Yes	28 (5.4)
FIGO stage
I	404 (77.7)
II	37 (7.1)
III	62 (11.9)
IV	17 (3.3)
Histological grade
Grade 1	161 (31.0)
Grade 2	232 (44.6)
Grade 3	127 (24.4)
Histological type
Type I	455 (87.5)
Type II	65 (12.5)
Tumor diameter
<2 cm	189 (36.3)
≥2 cm	331 (63.7)
Peritoneal cytology
No	473 (91.0)
Yes	47 (9.0)
LVSI
No	331 (74.4)
Yes	114 (25.6)
Lymph node involvement
No	401 (77.1)
Yes	49 (9.4)
Unknown	70 (13.5)
Lymphadenectomy
No	70 (13.5)
Yes	450 (86.5)
Adjuvant therapy
No adjuvant therapy	285 (54.8)
Radiotherapy	10 (2.0)
Chemotherapy	165 (31.7)
Radiotherapy +  cChemotherapy	60 (11.5)
Recurrence
No	474 (91.2)
Yes	46 (8.8)
Follow-up (months)
Median	53
Mean	48.7
Range	1–110

Data are expressed as n (%) or the means ± SD. FIGO = International Federation of Gynecology and Obstetrics; LVSI = lymphovascular space involvement.